Grade 1 skin GVHD in 6.7% (1/15), grade 2 skin GVHD in 6.7%, and acute hepatic GVHD grade 2-3 in 13.3% (2/15)
17% grade 3 and grade 4
Skin GVHD grade II in 18.2%, grade I GVHD of liver in 13.6%, and grades II-III gut GVHD in 9%
Data not available
Mortality rate
No mortality for the first month; 100 day mortality 8%; overall mortality 40% with the median follow-up of 39 months
Overall mortality is approximately 28%
Overall mortality was 13.7% at the median follow-up of 4.6 years
Mortality rate for allogeneic transplant is approximately 30% and for autologous transplant it is approximately 10% after 3 years of follow-up.(USA and Canada) [10]
Long term survival
Overall survival for thalassemia patients, autologous HSCT patients, and allogeneic HSCT patients was 66%, 65.7, and 57.1%, respectively, with median follow-up of 39 months
Overall survival 72.3 ± 3.1% of 218 patients of thalassemia at median follow-up of 5 years
Overall survival 86.3%; disease-free survival 68.2% seen at median follow-up of 22 patients for 4.6 years
50–70% in chronic leukaemias and 80–90% with aplastic anaemias (USA and Canada) [11]